Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

10.6%

12 terminated/withdrawn out of 113 trials

Success Rate

89.2%

+2.7% vs industry average

Late-Stage Pipeline

42%

47 trials in Phase 3/4

Results Transparency

51%

50 of 99 completed trials have results

Key Signals

1 recruiting50 with results8 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 3
42(43.8%)
Phase 2
22(22.9%)
Phase 1
21(21.9%)
Phase 4
5(5.2%)
N/A
5(5.2%)
Early Phase 1
1(1.0%)
96Total
Phase 3(42)
Phase 2(22)
Phase 1(21)
Phase 4(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (113)

Showing 20 of 113 trials
NCT00686595Phase 4Completed

A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

Role: collaborator

NCT01277419Recruiting

German Spondyloarthritis Inception Cohort

Role: collaborator

NCT01266785Not ApplicableWithdrawn

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Role: collaborator

NCT00833170Completed

Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry

Role: collaborator

NCT00705484Completed

European Safety Registry in Ulcerative Colitis (P04808)

Role: collaborator

NCT00656448Phase 3Completed

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Role: collaborator

NCT01144143Phase 4Completed

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

Role: collaborator

NCT00718718Phase 2Completed

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Role: lead

NCT01362153Phase 1Completed

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Role: lead

NCT00512278Phase 2Completed

Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C

Role: collaborator

NCT00925574Phase 1Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Role: lead

NCT00687401Phase 3Completed

A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

Role: collaborator

NCT00686686Phase 3Completed

Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)

Role: collaborator

NCT00686894Phase 4Terminated

Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)

Role: collaborator

NCT00791557Not ApplicableCompleted

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Role: collaborator

NCT01090063Not ApplicableCompleted

Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis

Role: collaborator

NCT00688636Phase 4Completed

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

Role: collaborator

NCT00111917Phase 1Terminated

Beryllium Infliximab Study: Clinical Interventional Trial

Role: collaborator

NCT01216631Phase 2Terminated

Seronegative Oligoarthritis of the Knee Study (SOKS)

Role: collaborator

NCT00786201Phase 2Completed

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead